Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy-Reference-Cited by-同舟云学术

Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer population in Xinjiang, China, and their impact on the prognosis of immunotherapy

Published:2024-09-07 Issue:9 Volume:150 Page:
ISSN:1432-1335
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Gu Guomin,Liu Chunling,Zhu Xiaodan,Yang Yan,Song Shuming,Zhao Yan,Sun Gang

Funder

Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region

Department of Science and Technology of Xinjiang Uygur Autonomous Region

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00432-024-05932-x.pdf

Reference38 articles.

1. Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, Massarelli E, Koczywas M, Reckamp K, Salgia R (2020) Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Disease 12(9):5086–5095

2. Aredo J, Padda S, Kunder C, Han S, Neal J, Shrager J, Wakelee H (2019) Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung cancer (Amsterdam Netherlands) 133:144–150

3. Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen W, Percent I, Gutierrez Calderon V, Johnson M, Madroszyk-Flandin A, Garon E et al (2024) SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. Annals Oncology: Official J Eur Soc Med Oncol 35(1):66–76

4. Cai D, Hu C, Li L, Deng S, Yang J, Han-Zhang H, Li M (2020) The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients. Cancer Med 9(1):84–93

5. Cao H, Ma Z, Huang Q, Han H, Li Y, Zhang Y, Chen H (1990) Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma. European journal of cancer (Oxford, England: 2024, 202:113985